Starling Oncology, Inc.
corporate_fare Company Profile
Starling Oncology, Inc. (NASDAQ:STLN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 3 items for STLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for STLN spans 4, 10-Q.
Recent high-impact activity:
- 10% Owner Chernett Sells $11.4M of Starling Stock, Buys Small Share/Option Lots, Owes 16(b) Disgorgement
- Starling Oncology Q3 10-Q: Revenue Up 24.3%, $11.6M Debt-Extinguishment Loss, Going-Concern Language
- Starling Oncology Posts Second Straight Positive Adjusted EBITDA, Raises Low End of FY26 Outlook
Financial Snapshot
Short Interest & Short Volume
5.42 days to coverFINRA reported short interest of 6,840,807 shares in STLN as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On November 20, 2026, 11.8% of STLN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.